Citadel Advisors
LKFT

Citadel Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Citadel Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Buy
+12,300
New +$407K ﹤0.01% 9993
2025
Q4 		– Sell
-9,600
Closed -$333K – 13172
2025
Q3 		$333K Buy
9,600
+800
+9% +$25.6K ﹤0.01% 10127
2025
Q2 		$246K Buy
8,800
+400
+5% +$10.7K ﹤0.01% 10247
2025
Q1 		$211K Sell
8,400
-7,300
-46% -$184K ﹤0.01% 10344
2024
Q4 		$432K Buy
15,700
+4,100
+35% +$114K ﹤0.01% 8889
2024
Q3 		$334K Sell
11,600
-2,300
-17% -$62.6K ﹤0.01% 9099
2024
Q2 		$344K Buy
13,900
+4,100
+42% +$116K ﹤0.01% 8868
2024
Q1 		$316K Buy
9,800
+3,200
+48% +$119K ﹤0.01% 9350
2023
Q4 		$268K Sell
6,600
-2,400
-27% -$88.3K ﹤0.01% 9379
2023
Q3 		$311K Sell
9,000
-16,000
-64% -$623K ﹤0.01% 9096
2023
Q2 		$1.02M Sell
25,000
-10,600
-30% -$432K ﹤0.01% 6422
2023
Q1 		$1.38M Sell
35,600
-20,800
-37% -$855K ﹤0.01% 6092
2022
Q4 		$2.5M Buy
56,400
+38,400
+213% +$1.62M ﹤0.01% 5066
2022
Q3 		$768K Buy
18,000
+2,400
+15% +$123K ﹤0.01% 7563
2022
Q2 		$870K Sell
15,600
-6,000
-28% -$356K ﹤0.01% 7342
2022
Q1 		$1.34M Buy
21,600
+300
+1% +$18.4K ﹤0.01% 7010
2021
Q4 		$1.17M Sell
21,300
-24,700
-54% -$1.29M ﹤0.01% 7553
2021
Q3 		$2.42M Buy
46,000
+400
+0.9% +$23.7K ﹤0.01% 5883
2021
Q2 		$3.14M Sell
45,600
-16,400
-26% -$1.25M ﹤0.01% 5488
2021
Q1 		$4.78M Buy
62,000
+37,600
+154% +$3.46M ﹤0.01% 4357
2020
Q4 		$2.42M Sell
24,400
-7,600
-24% -$929K ﹤0.01% 4966
2020
Q3 		$4.54M Buy
32,000
+17,900
+127% +$2.98M ﹤0.01% 3299
2020
Q2 		$2.78M Buy
14,100
+2,400
+21% +$497K ﹤0.01% 3986
2020
Q1 		$2.29M Buy
11,700
+1,200
+11% +$258K ﹤0.01% 3921
2019
Q4 		$2.17M Sell
10,500
-5,900
-36% -$1.09M ﹤0.01% 4277
2019
Q3 		$2.5M Sell
16,400
-900
-5% -$147K ﹤0.01% 4127
2019
Q2 		$2.23M Buy
17,300
+12,100
+233% +$1.44M ﹤0.01% 4327
2019
Q1 		$612K Buy
+5,200
New +$524K ﹤0.01% 6439
2018
Q4 		– Sell
-2,600
Closed -$292K – 9352
2018
Q3 		$292K Buy
+2,600
New +$275K ﹤0.01% 7601

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's LKFT Position: Q1 2026 in Review

Citadel Advisors increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 39% in Q1 2026, buying an estimated $1.16M and bringing the position to 124,428 shares worth $3.73M. The position accounts for ﹤0.01% of the portfolio, ranked #4844.

Citadel Advisors first reported a position in LKFT in Q2 2015 and has held it in 38 quarters since. The position peaked at $31.2M in Q2 2021. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Citadel Advisors held 124,428 shares of Lakefront Biotherapeutics American Depositary Shares worth $3.73M as of Q1 2026.
  • Citadel Advisors bought 35,032 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.16M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4844 holding.
  • Citadel Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 38 quarters since.
  • Citadel Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $31.2M in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.